Management of immune‐mediated necrotizing myopathy
Muscle & Nerve · 2024
DOI: 10.1002/mus.28114 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Muscle & Nerve, 2024. Verfasst von Joome Suh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Myositis. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
The immune‐mediated necrotizing myopathies (IMNM) are autoimmune myositides clinically characterized by proximal predominant weakness and elevated creatine kinase (CK). They may be associated with autoantibodies (anti‐HMGCR, anti‐SRP), triggered by statin use (e.g., anti‐HMGCR myopathy), associated with cancer, or may be idiopathic. Immunotherapy is required to improve strength and decrease the CK level, but no therapies are currently approved by the U.S. Food and Drug Administration for the treatment of IMNM. The optimal treatment strategy for IMNM is currently unknown and wide practice variation exists in the management of this condition. However, observational studies and expert opinion suggest that certain therapies may be more effective for the different serological subtypes of IMNM. HMGCR IMNM often responds favorably to intravenous immunoglobulin (IVIG) even as monotherapy. Signal recognition peptide and seronegative IMNM typically require combination immunotherapy, most often consisting of an oral immunosuppressant, corticosteroids, and IVIG or rituximab. Patients often remain on immunotherapy for years and relapse is common during tapering of immunotherapy. Further studies are needed to guide the optimal management of these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Zitieren
APA
Suh, J., & Amato, A. A. (2024). Management of immune‐mediated necrotizing myopathy. Muscle & Nerve. https://doi.org/10.1002/mus.28114
Vancouver
Suh J, Amato AA. Management of immune‐mediated necrotizing myopathy. Muscle & Nerve. 2024. doi:10.1002/mus.28114
BibTeX
@article{Suh2024,
author = {Suh, Joome and Amato, Anthony A},
title = {Management of immune‐mediated necrotizing myopathy},
journal = {Muscle & Nerve},
year = {2024},
doi = {10.1002/mus.28114}
}
EUVIMED